Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-weekly insulin icodec versus once-daily insulin glargine U100 after switching from daily basal insulin in adults with type 2 diabetes
2023-506084-34-00Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 8
01
Overview
Phase 3 trial of insulin icodec and insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c from baseline to week 26. Started Apr 2024; status: completed.
02
Drugs
insulin icodecinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2023-506084-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506084-34-00.